Skip to main content

Table 3 Clinical, serological and virological characteristics in 13 rheumatoid arthritis (RA) patients with HBV reactivation during immunosuppressive therapy

From: Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice

Characteristics

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Patient 8

Patient 9

Patient 10

Patient 11

Patient 12

Patient 13

Age/Gender

53/M

39/F

42/F

54/F

71/F

26/F

45/F

55/F

36/F

54/M

17/F

21/M

51/F

Past history of hepatitis

no

yes

no

no

no

yes

no

no

no

yes

yes

yes

yes

HBeAg, baseline/reactivation

-/-

-/-

-/-

-/-

-/-

-/-

+/+

-/-

-/-

-/-

+/+

+/+

-/-

Viral loads at baseline (Copies/mL)

<103

<103

<103

1.0 × 103

<103

<103

<103

<103

7.03 × 103

1.22 × 103

3.18 × 105

<103

1.0 × 103

Viral loads at reactivation (Copies/mL)

3.64 × 105

7.87 × 103

1.92 × 103

2.47 × 104

6.98 × 103

1.15 × 104

3.01 × 103

4.01 × 103

9.91 × 105

1.41 × 107

1.78 × 108

5.26 × 107

1.59 × 107

ALT at baseline (U/L)

8

8

20

19

10

6

15

15

11

30

17

20

27

ALT at reactivation (U/L)

26

20

39

24

26

8

16

123

103

103

825

1880

1274

Therapeutic regimens during follow-up

 Corticosteroid

7.5-10 mg/d

no

no

2.5-10 mg/d

5-10 mg/d

10 mg/d

10 mg/d

2.5-10 mg/d

10 mg/d

7.5-10 mg/d

7.5-10 mg/d

no

5-7.5 mg/d

 DMARDs

MTX + LEF

MTX + HCQ + SSZ

MTX + LEF

MTX + HCQ

MTX + SSZ

LEF

MTX + HCQ + SSZ

MTX + LEF

MTX + HCQ + SSZ

MTX + HCQ

MTX + LEF

LEF

MTX + HCQ + SSZ

Antiviral prophylaxis

no

Dis

no

Dis

Dis

no

no

no

LAM

LAM

Dis

Dis

no

Time to reactivation (months)

22

24

26

15

10

18

3

22

8

14

5

6

25

Follow-up period (months)

33

43

34

25

22

35

6

52

10

18

11

7

25

HBV hepatitis

no

no

no

no

no

no

no

Anicteric

Anicteric

Anicteric

Icteric

Icteric

Icteric, cirrhosis

Treatment adjustment after HBV reactivation

 Adjustments in DMARDs

MTX + HCQ + SSZ

no

no

no

no

no

no

HCQ

MTX + HCQ + SSZ

HCQ

SSZ

HCQ

withdrawal

 Antiviral drugs

LAM

no

no

no

no

no

no

LAM

Adefovir dipivoxil

telbivudine

LAM

entecavir

telbivudine

  1. The sequences of patients were numbered according to the date of HBV reactivation.
  2. HBV = Hepatitis B virus; F = female; M = male; HBeAg = antigen e of HBV; ALT = alanine aminotransferase; DMARDs = disease-modifying antirheumatic drugs; MTX = methrotrexate; LEF = Leflunomide; HCQ = hydroxychloroquine; SSZ = sulfasalazine.
  3. Dis = Discontinuation; LAM = lamivudine.